Experiments from the current study showed that SETDB1 loss in hypoxia hyperactivates immune-inflammatory responses by increasing TE-derived dsRNAs, suggesting that combination of immune checkpoint blockade and SETDB1 inactivation is more efficacious for cancer cells with hypoxic TME. Here, SETDB1 is linked to cancer.